These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27494968)

  • 1. [Not Available].
    Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F
    Clin Lung Cancer; 2016 May; 17(3):161-8. PubMed ID: 26908078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
    Ulmeanu R; Antohe I; Anisie E; Antoniu S
    Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
    Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
    J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding immunotherapy for the treatment of non-small cell lung cancer.
    Thomas R
    Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
    Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
    Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
    Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
    Kazandjian D; Khozin S; Blumenthal G; Zhang L; Tang S; Libeg M; Kluetz P; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):118-22. PubMed ID: 26470053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab--an effective second-line treatment for NSCLC.
    Romero D
    Nat Rev Clin Oncol; 2015 Dec; 12(12):685. PubMed ID: 26483299
    [No Abstract]   [Full Text] [Related]  

  • 11. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
    Rounds A; Kolesar J
    Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
    Remon J; Besse B; Soria JC
    BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune checkpoint inhibitors in lung cancer].
    Koleczko S; Wolf J
    Internist (Berl); 2020 Jul; 61(7):676-681. PubMed ID: 32462250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nivolumab, a new hope in non-small cell lung cancer].
    Flippot R; Fallet V; Besse B; Massard C; Wislez M; Vignot S
    Bull Cancer; 2015 Dec; 102(12):1046-52. PubMed ID: 26585939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab Outperforms Docetaxel for NSCLC.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
    [No Abstract]   [Full Text] [Related]  

  • 17. Nivolumab: a review in advanced squamous non-small cell lung cancer.
    Keating GM
    Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Hasegawa T; Uno H; Wei LJ
    N Engl J Med; 2016 Feb; 374(5):492-3. PubMed ID: 26840145
    [No Abstract]   [Full Text] [Related]  

  • 20. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
    Gyawali B; Ota A; Ando Y
    N Engl J Med; 2016 Feb; 374(5):493. PubMed ID: 26840146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.